Switching tumor necrosis factor α inhibitors in HLA–B27-associated severe heel enthesitis
Article first published online: 29 NOV 2007
Copyright © 2007 by the American College of Rheumatology
Arthritis Care & Research
Volume 57, Issue 8, pages 1572–1574, 15 December 2007
How to Cite
Olivieri, I., Scarano, E., Padula, A., D'angelo, S. and Cantini, F. (2007), Switching tumor necrosis factor α inhibitors in HLA–B27-associated severe heel enthesitis. Arthritis & Rheumatism, 57: 1572–1574. doi: 10.1002/art.23096
- Issue published online: 29 NOV 2007
- Article first published online: 29 NOV 2007
- Manuscript Accepted: 11 MAY 2007
- Manuscript Received: 21 FEB 2007
- 5Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [published erratum appears in Arthritis Rheum 2005;52:2951]. Arthritis Rheum 2005; 52: 1227–36., , , , , , et al.
- 6Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279–89., , , , , , et al, and the
- 7British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007; 56: 13–20., , , , , and the
- 8Switching from infliximab to once-weekly administration of 50 mg of etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four–week study. Arthritis Rheum 2006; 55: 812–6., , , , , , et al.